Trial · NCT02740179

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

NCT02740179, Not applicable, Completed, Massachusetts General Hospital; results first posted 2023-06-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study). Trials, record NCT02740179. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02740179

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
NCT number: NCT02740179
Status: Completed
Phases: Not applicable
Enrollment: 40 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: HIV
Interventions: Eplerenone, Placebo, Lifestyle Modification
First posted: 2016-04-15
Last updated: 2023-06-06
Results first posted: 2023-06-02

Source ClinicalTrials.gov

Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Myocardial Perfusion by PET	12 Months	Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by coronary flow reserve measured via cardiac positron emission tomography. Coronary flow reserve is given by the ratio of blood flow at stress during maximal dilation of the coronary arteries to blood flow at rest.
Primary	Myocardial Perfusion by MRI	12 Months	Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by myocardial blood flow measured via cardiac magnetic resonance imaging
Primary	Myocardial Inflammation	12 Months	Change (value at 12 months minus value at baseline) in myocardial inflammation measured by extracellular mass index (a measure of the inflammation within the heart) via cardiac magnetic resonance imaging
Secondary	Coronary Plaque	12 Months	Change (value at 12 months minus value at baseline) in coronary plaque measured via coronary computed tomography angiogram assessed by coronary calcium score Scale: minimum 0 to maximum no limit, higher score indicates more plaque
Secondary	Markers of Vascular Dysfunction	12 Months	Change (value at 12 months minus value at baseline) in serum hs-cTnT
Secondary	Markers of Systemic Inflammation hsIL-6	12 Months	Change (value at 12 months minus value at baseline) in plasma hsIL-6
Secondary	Markers of Systemic Inflammation hsCRP	12 Months	Change (value at 12 months minus value at baseline) in plasma hsCRP
Secondary	Markers of Immune Activation MCP-1	12 Months	Change (value at 12 months minus value at baseline) in plasma MCP-1
Secondary	Markers of Immune Activation sCD163	12 Months	Change (value at 12 months minus value at baseline) in plasma sCD163
Secondary	Markers of Subclinical Injury	12 Months	Change (value at 12 months minus value at baseline) in serum NT-proBNP

1 to 10 of 16Source ClinicalTrials.gov

See all 16 registered outcomes

Outcomes16

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Myocardial Perfusion by PET	12 Months	Analyses performed on data available	unitless	MEAN
PRIMARY	Myocardial Perfusion by MRI	12 Months	Analyses performed on data available	mL/min/g	MEAN
PRIMARY	Myocardial Inflammation	12 Months	Analyses performed on data available	g/m^2	MEDIAN
SECONDARY	Coronary Plaque	12 Months	Analyses performed on data available	score on a scale	MEDIAN
SECONDARY	Markers of Vascular Dysfunction	12 Months	Analyses performed on data available	ng/L	MEDIAN
SECONDARY	Markers of Systemic Inflammation hsIL-6	12 Months	Analyses performed on data available	pg/mL	MEDIAN
SECONDARY	Markers of Systemic Inflammation hsCRP	12 Months	Analyses performed on data available	ng/mL	MEDIAN
SECONDARY	Markers of Immune Activation MCP-1	12 Months	Analyses performed on data available	pg/mL	MEDIAN
SECONDARY	Markers of Immune Activation sCD163	12 Months	Analyses performed on data available	ng/mL	MEDIAN
SECONDARY	Markers of Subclinical Injury	12 Months	Analyses performed on data available	ng/L	MEDIAN

1 to 10 of 16Source ClinicalTrials.gov

See all 16 outcomes

Results by group32

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Myocardial Perfusion by PET	Eplerenone	0.01	Standard Deviation 0.64	unitless
Myocardial Perfusion by PET	Placebo	-0.07	Standard Deviation 0.48	unitless
Myocardial Perfusion by MRI	Eplerenone	0.09	Standard Deviation 0.56	mL/min/g
Myocardial Perfusion by MRI	Placebo	-0.53	Standard Deviation 0.68	mL/min/g
Myocardial Inflammation	Eplerenone	0.9	Inter-Quartile Range -2.3 to 4.3	g/m^2
Myocardial Inflammation	Placebo	-0.7	Inter-Quartile Range -2.2 to -0.1	g/m^2
Coronary Plaque	Eplerenone	0	Inter-Quartile Range 0 to 6	score on a scale
Coronary Plaque	Placebo	5	Inter-Quartile Range 0 to 41	score on a scale
Markers of Vascular Dysfunction	Eplerenone	0.00	Inter-Quartile Range -0.13 to 0.00	ng/L
Markers of Vascular Dysfunction	Placebo	0.00	Inter-Quartile Range 0.00 to 0.74	ng/L

1 to 10 of 32Source ClinicalTrials.gov

See all 32 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Eplerenone	20
Overall Study	STARTED	Placebo	20
Overall Study	COMPLETED	Eplerenone	14
Overall Study	COMPLETED	Placebo	19
Overall Study	NOT COMPLETED	Eplerenone	6
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.gov

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dizziness	Cardiac disorders	Eplerenone	4	20
other	Dizziness	Cardiac disorders	Placebo	0	20
other	Gastrointestinal Symptoms	Gastrointestinal disorders	Eplerenone	4	20
other	Gastrointestinal Symptoms	Gastrointestinal disorders	Placebo	3	20
other	Rash	Skin and subcutaneous tissue disorders	Eplerenone	3	20
other	Rash	Skin and subcutaneous tissue disorders	Placebo	1	20
other	Upper Respiratory Infection	Respiratory, thoracic and mediastinal disorders	Eplerenone	3	20
other	Upper Respiratory Infection	Respiratory, thoracic and mediastinal disorders	Placebo	1	20
other	Other Infection	Infections and infestations	Eplerenone	5	20
other	Other Infection	Infections and infestations	Placebo	6	20

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Eplerenone	1	20
Total, all-cause mortality	Placebo	0	20
Total, other adverse events	Eplerenone	12	20
Total, other adverse events	Placebo	11	20
Total, serious adverse events	Eplerenone	1	20
Total, serious adverse events	Placebo	0	20

Source ClinicalTrials.gov

Papers7

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
26086328	BACKGROUND	PubMed
37243345	DERIVED	PubMed
37559752	DERIVED	PubMed
38090987	DERIVED	PubMed
38813261	DERIVED	PubMed
40478895	DERIVED	PubMed
41994349	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Eplerenone vs Placebo: deaths from any cause	Trial comparisons
Eplerenone vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02740179

GET https://conductscience.org/api/trials/v1/NCT02740179/results?page=2

API reference For AI assistants